BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2020 7:11:20 AM | Browse: 908 | Download: 1906
Publication Name World Journal of Diabetes
Manuscript ID 58060
Country Greece
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Editorial
Article Title Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
Manuscript Source Invited Manuscript
All Author List Stavroula Veneti and Konstantinos Tziomalos
ORCID
Author(s) ORCID Number
Stavroula Veneti http://orcid.org/0000-0002-4970-6982
Konstantinos Tziomalos http://orcid.org/0000-0002-3172-1594
Funding Agency and Grant Number
Corresponding Author Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Key Words Diabetic nephropathy; Type 2 diabetes mellitus; Glucagon-like peptide-1 receptor agonists; Liraglutide; Dulaglutide; Semaglutide
Core Tip Glucagon-like peptide-1 receptor agonists prevent the development of persistent macroalbuminuria in patients with type 2 diabetes mellitus. However, it is unclear whether they delay the decline in glomerular filtration rate in this population. Long-term trials are needed to clarify the role of these agents in the management of diabetic nephropathy.
Publish Date 2020-09-11 07:11
Citation Veneti S, Tziomalos K. Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy? World J Diabetes 2020; 11(9): 370-373
URL https://www.wjgnet.com/1948-9358/full/v11/i9/370.htm
DOI https://dx.doi.org/10.4239/wjd.v11.i9.370
Full Article (PDF) WJD-11-370.pdf
Full Article (Word) WJD-11-370.docx